Pulmonary fibrosis: Is inflammation friend or foe?

Pulmonary fibrosis, particularly in its idiopathic form, remains a devastating diagnosis with limited therapeutic options. The heterogeneity of fibrotic interstitial lung diseases (fILDs) means that a one-size-fits-all approach to treatment often fails, necessitating a deeper understanding of underlying pathomechanisms.¹ These diseases can arise from persistent inflammation triggered by systemic conditions or environmental exposures, but the degree to which inflammation drives or results from fibrosis varies widely across different fILDs.¹

Nazemi and colleagues explored the intricate relationship between inflammation and fibrosis in their comprehensive review, highlighting that these are not discrete, sequential events but rather dynamically intertwined processes.¹ The authors, including N. Nazemi, B. Crestani, and D.G. Helou, from institutions across Europe, synthesized insights from experimental models and translational research to advance the understanding of these complex interactions.¹ Their work emphasizes that the nature and relative importance of these interactions are highly dependent on the underlying etiology of the fILD.¹

The Dynamic Relationship of Inflammation and Fibrosis

Inflammation can function as both a driver and a consequence of fibrotic remodeling, establishing self-perpetuating feed-forward loops that exacerbate disease progression.¹ But, inflammation also plays a role in fibrosis resolution and control, adding another layer of complexity to its therapeutic targeting.¹ This dual nature means that simply suppressing inflammation may not always be beneficial, especially in conditions like IPF where inflammation is often limited, and fibrosis is the dominant feature.¹

The review details how fibrotic and inflammatory signaling pathways show considerable overlap, and their interaction is central to disease initiation and progression.¹ For instance, various cytokines and growth factors, such as TGF-β, TNF-α, and IL-6, are implicated in both inflammatory responses and profibrotic signaling.¹ Understanding these shared pathways offers opportunities for targeted interventions that could modulate both processes simultaneously.¹ This is particularly relevant given the broad spectrum of disease phenotypes observed within most fILDs, where the balance between inflammation and fibrosis is only partially determined by the underlying diagnosis.¹

Elucidating the mechanisms that govern cellular responses to diverse injurious stimuli provides an opportunity to refine patient stratification and tailor therapies to improve outcomes.¹ For example, in fILDs with a significant inflammatory component, anti-inflammatory therapies might be more effective, whereas in predominantly fibrotic diseases, antifibrotic agents would be the primary choice.¹ The challenge lies in accurately identifying the dominant pathological process in individual patients, a task that current diagnostic tools do not always accomplish with sufficient precision.¹

Current Therapeutic Approaches and Their Limitations

Current therapeutic strategies for fILDs largely bifurcate into anti-inflammatory and antifibrotic approaches.¹ For conditions with a clear inflammatory driver, such as connective tissue disease-associated ILDs, immunosuppressive agents like corticosteroids, azathioprine, or mycophenolate mofetil often form the backbone of treatment.¹ These agents aim to dampen the immune response and prevent further tissue damage.¹ But, their efficacy in purely fibrotic conditions like IPF is limited, and prolonged use carries significant side effects.¹

In IPF, the antifibrotic drugs nintedanib and pirfenidone have shown efficacy in slowing disease progression.¹ Nintedanib, a tyrosine kinase inhibitor, targets multiple pathways involved in fibrosis, including PDGF, FGF, and VEGF receptors.¹ Pirfenidone, an oral antifibrotic agent, reduces fibroblast proliferation and collagen synthesis.¹ Both drugs reduce the rate of decline in forced vital capacity (FVC) but do not reverse established fibrosis or cure the disease.¹ Their use is associated with side effects such as gastrointestinal disturbances and liver enzyme elevations, which can impact patient adherence.¹

The problem is that these antifibrotic agents are not universally effective, and a substantial proportion of patients continue to experience disease progression despite treatment.¹ This highlights the unmet need for therapies that can more effectively halt or even reverse fibrosis.¹ The limited efficacy of current treatments emphasizes the importance of a personalized approach, where therapies are matched to the specific pathomechanisms driving an individual patient's disease.¹ Clinicians seeking a concise guide to modern respiratory practice may find the Oxford Handbook of Respiratory Medicine a useful reference for these complex decisions.

Emerging Targets and Future Directions

Translational research has identified several emerging therapeutic targets that aim to disrupt the feed-forward loops between inflammation and fibrosis.¹ These include pathways involved in epithelial cell injury and repair, fibroblast activation, and extracellular matrix remodeling.¹ For example, targeting specific inflammatory mediators or their receptors, or inhibiting profibrotic signaling molecules, could offer novel avenues for intervention.¹

One area of intense investigation involves the role of specific immune cell subsets in driving fibrosis.¹ While IPF is characterized by limited inflammation, other fILDs show variable contributions.¹ For instance, certain T-cell subsets and macrophages can either promote or resolve fibrosis depending on their activation state and cytokine profile.¹ Modulating these immune cells, perhaps through novel immunomodulatory agents, could offer a more specific approach than broad immunosuppression.¹ This is a concept explored in other fields, such as in chronic graft-versus-host disease, where CAR19 Tregs have shown the ability to suppress immune responses without measurable B cell cytolysis in murine models.³ While not directly applicable to pulmonary fibrosis, this work illustrates the potential for highly specific immune modulation.³

The development of biomarkers that can accurately distinguish between inflammatory and fibrotic phenotypes is also critical.¹ Such biomarkers would allow for earlier and more precise patient stratification, guiding treatment decisions towards the most appropriate therapy.¹ Imaging techniques, such as advanced CT scans and PET scans, are also being explored for their ability to quantify inflammatory and fibrotic burden in the lungs.¹

Another direction involves therapies that directly target the fibrotic process by promoting the degradation of extracellular matrix or inhibiting fibroblast activation.¹ This could include agents that modulate lysyl oxidase activity, an enzyme involved in collagen cross-linking, or those that interfere with the activation of myofibroblasts, the primary collagen-producing cells in fibrotic tissue.¹ The challenge remains to develop agents that are highly specific to fibrotic pathways without causing undue systemic toxicity.¹

The concept of reversing fibrosis, rather than merely slowing its progression, represents the ultimate goal.¹ While this remains largely aspirational, experimental models have provided some evidence that fibrosis can be, at least partially, reversible under certain conditions.¹ This suggests that therapies aimed at reactivating endogenous antifibrotic mechanisms or promoting tissue regeneration could hold significant potential.¹

The Need for Personalized Medicine

The heterogeneity of fILDs demands a personalized medicine approach.¹ This means moving beyond a single diagnosis and instead characterizing each patient's disease based on its unique molecular and cellular profile.¹ Genetic factors, environmental exposures, and comorbidities all contribute to the diverse phenotypes observed in fILDs.¹ For example, patients with systemic sclerosis often develop ILD, and the inflammatory component in these cases may differ significantly from that in IPF.¹ Our previous coverage on systemic sclerosis and pulmonary tuberculosis risk highlights the complex relationship of systemic disease and lung pathology.

Integrating multi-omics data (genomics, transcriptomics, proteomics, metabolomics) with clinical and imaging data could provide a more comprehensive picture of each patient's disease.¹ This would enable clinicians to select therapies that are most likely to be effective for that individual, minimizing trial-and-error and improving outcomes.¹ The insights from experimental models of pulmonary fibrosis and translational research have significantly advanced our understanding of these processes, but translating this knowledge into routine clinical practice remains a substantial hurdle.¹

The review by Nazemi, Crestani, and Helou emphasizes that while progress has been made, significant opportunities for improving outcomes in pulmonary fibrosis still exist.¹ The focus must shift towards a more granular understanding of the dynamic relationship between inflammation and fibrosis, allowing for the development of tailored therapies.¹ This will require continued investment in basic and translational research, as well as the development of robust clinical trials designed to test these personalized approaches.¹

The challenge lies in the sheer complexity of these diseases.¹ The review acknowledges that while inflammation can drive fibrosis, it can also contribute to its resolution.¹ This dual role means that therapeutic interventions must be carefully calibrated to avoid disrupting beneficial inflammatory processes while targeting detrimental ones.¹ The lack of universally accepted biomarkers to precisely differentiate these roles in individual patients remains a significant limitation.¹

Still, the emphasis on refining patient stratification and tailoring therapies based on a deeper understanding of pathomechanisms offers a clear path forward.¹ This approach moves beyond broad classifications and aims to address the specific drivers of disease in each patient, representing a more sophisticated strategy for managing these challenging conditions.¹